Immunotech Biopharm Ltd (HK:6978)
:6978
Want to see HK:6978 full AI Analyst Report?
Top Page
Immunotech Biopharm Ltd
(6978)
Select Model
Select Model
Rating:41Neutral
Price Target:
HK$0.81
▼(-69.70% Downside)
Action:Upgraded
Date:05/08/26
The score is primarily constrained by weak financial performance (no revenue, ongoing losses, continued cash burn, and negative equity) and a very bearish technical setup (price well below major moving averages with negative MACD and very weak momentum). Valuation metrics provide limited support because the company is loss-making (negative P/E) and no dividend yield is available.
Positive Factors
Deleveraging
The sharp reduction in reported total debt from 784.0M (2023) to 103.7M (2025) materially lowers gross leverage. Sustained deleveraging reduces refinancing and interest burden, improving financing optionality and giving management structural flexibility for R&D, partnerships or contingency funding.
Negative Factors
No reported revenue
A complete absence of reported revenue across 2020–2025 defines a pre‑commercial profile with no proven cash‑generating product. Long‑term viability therefore hinges on successful approvals, partnerships or licensing; until then the company lacks operational cash flow and faces high execution and commercialization risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Deleveraging
The sharp reduction in reported total debt from 784.0M (2023) to 103.7M (2025) materially lowers gross leverage. Sustained deleveraging reduces refinancing and interest burden, improving financing optionality and giving management structural flexibility for R&D, partnerships or contingency funding.
Read all positive factors
Immunotech Biopharm Ltd (6978) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$512.53M
Dividend YieldN/A
Average Volume (3M)1.34M
Price to Earnings (P/E)―
Beta (1Y)0.54
Revenue GrowthN/A
EPS Growth-25.79%
CountryHK
Employees154
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.42
Shares Outstanding617,500,800
10 Day Avg. Volume1,608,107
30 Day Avg. Volume1,338,788
Financial Highlights & Ratios
PEG Ratio-0.46
Price to Book (P/B)-103.70
Price to Sales (P/S)0.00
P/FCF Ratio-12.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Immunotech Biopharm Ltd Business Overview & Revenue Model
Company Description
Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People's Republic of China. Its core prod...
How the Company Makes Money
null...
Immunotech Biopharm Ltd Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
16
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -53.87M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -115.49M | -148.68M | -178.83M | -231.11M | -324.33M |
| Net Income | -224.81M | -186.91M | -334.82M | -318.11M | -354.22M |
Balance Sheet | |||||
| Total Assets | 603.20M | 564.04M | 846.28M | 879.44M | 1.10B |
| Cash, Cash Equivalents and Short-Term Investments | 154.63M | 57.49M | 176.97M | 79.46M | 353.34M |
| Total Debt | 440.26M | 384.56M | 784.01M | 149.81M | 111.05M |
| Total Liabilities | 569.01M | 580.50M | 675.39M | 373.07M | 274.51M |
| Stockholders Equity | -13.93M | -13.30M | 173.62M | 508.44M | 822.26M |
Cash Flow | |||||
| Free Cash Flow | -111.92M | -153.81M | -186.17M | -277.49M | -435.89M |
| Operating Cash Flow | -97.29M | -125.74M | -163.63M | -180.92M | -254.65M |
| Investing Cash Flow | -98.07M | 141.10M | -116.60M | 23.38M | -328.21M |
| Financing Cash Flow | 203.20M | -20.59M | 273.92M | -36.06M | -11.00M |
Immunotech Biopharm Ltd Technical Analysis
Negative
2.68
Price Trends
2.30
Negative
2.48
Negative
3.16
Negative
Market Momentum
-0.52
Positive
23.04
Positive
19.98
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6978, the sentiment is Negative. The current price of 2.68 is above the 20-day moving average (MA) of 1.51, above the 50-day MA of 2.30, and below the 200-day MA of 3.16, indicating a bearish trend. The MACD of -0.52 indicates Positive momentum. The RSI at 23.04 is Positive, neither overbought nor oversold. The STOCH value of 19.98 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6978.
Immunotech Biopharm Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | HK$3.51B | -3.96 | -14.53% | ― | -32.12% | -393.23% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$3.87B | -3.21 | -137.11% | ― | ― | 0.47% | |
47 Neutral | HK$1.45B | -4.01 | -12.64% | ― | -53.85% | 12.23% | |
45 Neutral | HK$924.98M | -7.27 | -15.19% | ― | ― | 20.16% | |
44 Neutral | HK$1.79B | -7.60 | -27.70% | ― | -100.00% | 50.29% | |
41 Neutral | HK$512.53M | -3.95 | 293.08% | ― | ― | -25.79% |
* Healthcare Sector Average
HK:6978
Immunotech Biopharm Ltd
0.84
-2.14
-71.81%
HK:1875
TOT BIOPHARM International Co. Ltd.
4.37
2.54
138.80%
HK:2179
Jiangsu Recbio Technology Co., Ltd. Class H
5.15
-3.91
-43.16%
HK:2185
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
3.50
0.94
36.72%
HK:3681
SinoMab Bioscience Ltd.
1.32
0.04
3.13%
HK:6622
Zhaoke Ophthalmology Ltd.
2.67
0.25
10.33%
Immunotech Biopharm Ltd Corporate Events
Immunotech Biopharm Shareholders Unanimously Back All AGM Resolutions
Apr 30, 2026
Immunotech Biopharm reported that all resolutions at its 30 April 2026 annual general meeting were approved by shareholders via poll, with 617,500,800 shares eligible to vote and no treasury or repurchased shares affecting the count. The company c...
Immunotech’s Conditional Liver Cancer Application for EAL Rejected, Firm Plans New Trial and Resubmission
Apr 28, 2026
Immunotech Biopharm Ltd has disclosed that China’s Center for Drug Evaluation has rejected its conditional new drug application for EAL in preventing postoperative recurrence of liver cancer, citing the need for confirmatory clinical trial d...
Immunotech Biopharm Halts Trading Pending Inside-Information Announcement
Apr 28, 2026
Immunotech Biopharm Ltd has requested a halt in trading of its shares on the Hong Kong Stock Exchange, effective from 1:00 p.m. on 28 April 2026. The suspension is pending the release of an announcement containing inside information, signaling tha...
Immunotech Biopharm Sets 2026 AGM With Share Mandate and Board Re-Elections on Agenda
Apr 7, 2026
Immunotech Biopharm has called its annual general meeting for 30 April 2026 in Beijing, where shareholders will review and adopt the audited consolidated financial statements and directors’ and auditor’s reports for the year ended 31 D...
Immunotech Biopharm Brings Forward 2026 AGM and Adjusts Book Closure Dates
Apr 7, 2026
Immunotech Biopharm Ltd has rescheduled its 2026 annual general meeting, moving it forward from 22 May to 30 April due to administrative reasons. The company confirmed that all previously announced AGM-related information remains unchanged apart f...
Immunotech Biopharm Widens Annual Loss as Cancer Cell Therapies Advance in China
Mar 20, 2026
Immunotech Biopharm reported that for the year ended 31 December 2025, other income fell sharply, research and administrative expenses declined, but net other losses surged, leading to an increased annual loss of RMB230.9 million compared with the...
Immunotech Biopharm Tightens Audit Committee Rules to Bolster Governance
Mar 20, 2026
Immunotech Biopharm Ltd has updated the terms of reference for its audit committee as of 20 March 2026, reaffirming the committee’s role in supporting the board on financial reporting, risk management and internal control, and in maintaining...
Immunotech Biopharm Updates Remuneration Committee Terms to Strengthen Governance
Mar 20, 2026
Immunotech Biopharm Ltd has updated the terms of reference for its remuneration committee, originally established in June 2020, with amendments effective 20 March 2026. The committee is tasked with recommending policies and structures for director...
Immunotech Biopharm Sets March Board Meeting to Approve 2025 Annual Results
Mar 10, 2026
Immunotech Biopharm Ltd has scheduled a board meeting for 20 March 2026 to review and approve the annual results of the company and its subsidiaries for the financial year ended 31 December 2025. The move signals the company is preparing its audit...
Immunotech Biopharm Places RMB50 Million in EUR/USD-Linked Structured Deposit
Feb 25, 2026
Immunotech Biopharm Ltd has placed RMB50 million into a principal-protected, floating-income structured deposit with SPD Bank, tying returns to movements in the EUR/USD spot exchange rate. The 29-day product, effective 2 March 2026 and maturing 31...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.